Real-World Impact of SUNLIGHT Outcomes in mCRC

Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.

EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

Now Viewing

EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC

EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2

EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions

EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care

EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

• The recent SUNLIGHT trial compared FTD/TPI monotherapy to FTD/TPI in combination with bevacizumab for advanced metastatic colorectal cancer. Describe the key takeaways from this trial.
• Include in your discussion overall survival, safety profile, as well as benefit seen regardless of prior bevacizumab therapy.
• How has the SUNLIGHT data impacted your overall use of FTD/TPI in the third-line setting?
• How do the outcomes in SUNLIGHT compare with what you’ve seen as real-word outcomes?

Related Videos

Related Content

Advertisement

March 28th 2025

Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-line Treatment of KRAS-mutated NSCLC

Mary Caffrey

Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 26th 2025

Prevalence, Severity of Astigmatism Increased in Children After Pandemic

Julia Bonavitacola

Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal changes potentially playing a part.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 26th 2025

PAH Therapies Improve Outcomes in PH-ILD

Maggie L. Shaw

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

Related Content

Advertisement

March 28th 2025

Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-line Treatment of KRAS-mutated NSCLC

Mary Caffrey

Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 26th 2025

Prevalence, Severity of Astigmatism Increased in Children After Pandemic

Julia Bonavitacola

Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal changes potentially playing a part.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 26th 2025

PAH Therapies Improve Outcomes in PH-ILD

Maggie L. Shaw

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.